Bristol Myers Squibb Q1 revenue rises 3% to $11.5 billion; non-GAAP EPS falls 12%
Bristol Myers Squibb reported first-quarter 2026 revenue of $11.5 billion, up 3% (1% excluding foreign exchange), while non-GAAP earnings per share fell 12% to $1.58 from $1.80. GAAP EPS rose 9% to $1.31, and the company reaffirmed its 2026 guidance, including non-GAAP EPS of $6.05 to $6.35, with results trending toward the upper end of the ranges.
Key points
- Growth Portfolio revenue rose 12% (9% ex-FX) to $6.2 billion, while Legacy Portfolio revenue fell 6% to $5.3 billion.
- Non-GAAP net income attributable to BMS was $3.2 billion ($1.58 per share), down from $3.7 billion ($1.80 per share) a year earlier.
- GAAP R&D expenses rose 17% to $2.6 billion, primarily due to IPRD impairment charges, and GAAP gross margin fell to 70.2% from 72.9%.
- 2026 guidance was reaffirmed with no changes from February: total revenues of about $46.0 billion to $47.5 billion and non-GAAP diluted EPS of $6.05 to $6.35.
The filing
Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.